TNFSF13B and systemic lupus erythematosus: Its knockdown in vitro results in decreased expression of select female-biased immune transcripts, including B cell–activating factor (BAFF; also known as B lymphocyte stimulator and TNFSF13B), the target of belimumab, the only biologic currently used to treat systemic lupus erythematosus [283].